SLC on an IBD drug: slcimmuno Member Level Tu
Post# of 72446
(Total Views: 317)
Posted On: 05/30/2017 1:32:02 PM
Re: someconcerns #34321
SLC on an IBD drug:
And Farai's note:
And more:
Quote:
slcimmuno Member Level Tuesday, 05/30/17 10:20:19 AM
Re: None
Post # of 183654
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Def money being thrown around in IBD -- pre-clinical.
/
Johnson & Johnson has landed rights to Protagonist Therapeutics’ preclinical Crohn’s disease asset PTG-200. The deal gives J&J a stake in an oral interleukin-23 (IL-23) receptor antagonist in return for $50 million upfront and up to $940 million in milestones.
/
The asset is due to enter the clinic this year. Protagonist will run and fund the trial with J&J taking over—and covering 80% of the costs—once it advances to phase 2. Beyond this, a series of major paydays await Protagonist. J&J will pay Protagonist $125 million if it moves the drug into phase 2b and a further $200 million if it sticks with the asset after getting a look at data from the trial. The rest of the cash is tied to regulatory and sales milestones.
http://www.fiercebiotech.com/biotech/j-j-comm...ohn-s-drug
And Farai's note:
Quote:
faraifarai Tuesday, 05/30/17 10:31:24 AM
Re: slcimmuno post# 183624
Post # of 183654
Scratching my eyes a bit, but pretty sure you and the dealmakers wrote: 'pre-clinical', which is one before 'clinical' and two before 'mid-stage'. Geeze-luis $1 B for a pre-clinical compound. Wonder what big pharma might pay for an IBD drug with 17 patient results with complete endoscopic assessment and foam formulation planned? mid-stage, mid-stage, mid-stage---phase 2 to be completed and reveal topline results July 10-13, 2017 in Boston.
And more:
Quote:
faraifarai Tuesday, 05/30/17 10:49:21 AM
Re: cabel post# 183627
Post # of 183654
And very favorable terms--super deal for the small guys. all of these deals just keeps setting the bar higher for what other big pharma would have to pay ctix. shows how competitive this space is. ctix is showing extreme efficacy and safety in the clinical setting right now. looking forward to Boston reveal--and what that may mean for a frenzied dealmaking summer...eyeing $20+ by Turkey Day.
(1)
(0)